Express Pharma
Home  »  Market  »  IPM grows 10.9 per cent, clocks Rs 7243 crores in November 2014

IPM grows 10.9 per cent, clocks Rs 7243 crores in November 2014

0 42
Read Article

11 therapies have outgrown the IPM growth and have double digit growths

The Indian Pharma Market (IPM) clocked Rs 7243 crores in November 2014 and has grown at 10.9 per cent. Amongst the top 10, Pfizer grew by 34.1 per cent followed by Ranbaxy at 23.1 per cent and Sun Pharma at 14.9 per cent. 21 corporates have crossed the growth of IPM amongst top 50.

Amongst the top 50 corporate, Akumentis has the highest growth of 68 per cent followed by Pfizer at 34.1 per cent and Ajanta at 33.1 per cent. 24 corporates have shown growths more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporates, Macleods has the highest growth of 24.6 per cent followed by Torrent at 23.3 per cent and Glenmark at 20.3 per cent. Amongst the 51-60 ranked corporates, Panacea grows at 31.3 per cent followed by Pharmed at 25.6 per cent and Corona at 21.9 per cent.

With Bonus Units at Full Value
Val in Crs
Rank
MAT Nov -14
Nov-14
CORPORATE
MAT
MTH
Val (Cr)
MS%
GR%
Val (Cr)
MS%
GR%
IPM
82095
100.00
9.9
7243
100.00
10.9
Abbott + Abbott HC + Novo
1
1
5067
6.17
6.2
449
6.20
10.2
Sun Pharma
2
2
4449
5.42
14.8
411
5.67
14.9
Cipla
3
3
4099
4.99
11.0
355
4.90
8.3
Zydus + Biochem
4
4
3565
4.34
7.9
317
4.38
7.4
Ranbaxy
5
5
2993
3.65
8.7
297
4.10
23.1
Mankind
6
6
2949
3.59
11.7
259
3.58
11.6
Alkem + Cachet + Indchemie
7
7
2903
3.54
12.5
255
3.52
5.6
GSK
8
9
2777
3.38
-5.2
235
3.24
5.7
Lupin
9
8
2740
3.34
12.2
238
3.29
8.2
Pfizer
10
10
2426
2.95
11.6
223
3.08
34.1
Macleods
11
11
2356
2.87
24.9
209
2.88
24.6
Emcure + Zuventus
12
13
2215
2.70
9.1
191
2.63
7.3
Intas
13
12
2147
2.61
15.5
192
2.66
16.2
Aristo
14
15
2052
2.50
19.3
178
2.46
7.6
Sanofi India
15
14
2030
2.47
3.8
188
2.60
18.2
Torrent
16
17
1820
2.22
7.9
168
2.32
23.3
Glenmark
17
16
1788
2.18
15.0
177
2.45
20.3
Dr Reddys
18
18
1748
2.13
9.2
152
2.10
9.4
Micro + Bal
19
20
1602
1.95
8.3
136
1.88
3.2
USV
20
19
1580
1.92
15.7
142
1.95
15.0
Ipca
21
21
1474
1.80
20.7
124
1.71
4.2
Novartis
22
23
1154
1.41
1.0
97
1.33
5.2

Amongst the 61-75 ranked Corporate, Boehringer grew by 83.5 per cent followed by TTK at 18 per cent and RPG at 16.3 per cent. Merck entered the Rs 500-crore club and Albert David in the Rs 300-crore Club as on MAT November 2014. Indian companies have grown at 9.5 per cent versus 14.9 per cent for MNCs in November 2014.

Amongst the top 50 in MNCs, Pfizer grew by 34.1 per cent followed by Merck at 24.5 per cent and Ranbaxy at 23.1 per cent. Under the non-NLEM category, Indian companies grew at 0.4 per cent whereas MNCs grew at 11.1 per cent.

The DPCO containing molecules market grew at 3.1 per cent whereas the non DPCO market grew by 12.6 per cent resulting in an overall growth of 10.9 per cent for November 2014. NLEM and non-NLEM category showed unit growth at -3.4 per cent and 0.3 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 20.9 per cent, GSK -1.5 per cent, Ranbaxy 34.3 per cent.

Val in Crs
MAT Nov 14
Month Nov-14
Super Group
Val in Crs
VAL GR%
Val in Crs
VAL GR%
IPM
82095
9.9
7243
10.9
ANTI-INFECTIVES
13198
5.7
1151
4.0
CARDIAC
10162
9.8
894
12.8
GASTRO INTESTINAL
9438
11.3
794
12.8
VITAMINS / MINERALS / NUTRIENTS
7425
10.9
640
13.9
RESPIRATORY
6337
11.1
616
4.1
ANTI DIABETIC
6124
20.0
559
23.8
PAIN / ANALGESICS
5893
9.0
511
8.1
NEURO / CNS
5103
7.8
450
11.2
DERMA
4701
16.0
445
19.3
GYNAECOLOGICAL
4176
4.5
348
7.9
OPHTHAL / OTOLOGICALS
1522
13.4
136
19.7
ANTI-NEOPLASTICS
1346
26.8
110
15.1
HORMONES
1344
4.8
118
8.7
VACCINES
1173
-7.3
96
-0.1
BLOOD RELATED
979
2.1
79
4.6
OTHERS
900
9.8
87
25.2
UROLOGY
858
20.2
78
28.3
ANTI MALARIALS
598
5.8
57
-7.5
SEX STIMULANTS / REJUVENATORS
458
3.4
42
8.7
STOMATOLOGICALS
358
11.8
31
13.7

From therapy perspective, 11 therapies have outgrown the IPM growth and have double digit growths. The respiratory market grew at 4.1 per cent, gastrointestinal market grew at 12.8 per cent, pain and analgesics market grew at 8.1 per cent whereas the anti-infectives grew at four per cent. The anti-diabetic market grows at 23.8 per cent and cardiac at 12.8 per cent in chronic business. The derma market grew by 19.3 per cent and the urology market at 28.3 per cent.

From regional perspective, 14 regions have outgrown the IPM growth. The Gujarat market grew the highest at 22.4 per cent followed by Chattisgarh market at 19.6 per cent and Madhya Pradesh market at 19.3 per cent. No regions had negative growth in November 2014.

Amoxycillin + Clavulanic acid market degrows at -1.4 per cent whereas Glimepiride + Metformin grows at 12.1 per cent at number two. The markets of paracetamol grew at two per cent, atorvastatin 18.2 per cent, probiotic microbes at 30.6 per cent, cefixime -2.2 per cent, pantoprazole 15 per cent, montelukast + levocetrizine at 13 per cent, glimepiride + metformin + pioglitazone at 25.2 per cent, vitamin-D at 35.7 per cent, hydroquinone + mometasone + tretinoin at 32 per cent, voglibose + metformin + glimepiride at 53.8 per cent, leveteracetam at 26.4 per cent, protein supplements at 22.7 per cent.

Mixtard continues to lead the pack with Rs 31.1 crores for the month of November14 with a growth of 16.7 per cent. Lantus grew at 41.2 per cent, glycomet- GP grows at 21.9 per cent, monocef grows at 10.2 per cent, augmentin grows at 3.2 per cent, amongst the top 10 brands.

Amongst the brands who have gained ranks include Glycomet-GP (+6), Lantus (+13), Dexorange (+3), Liv-52 (+7), Galvus Met (+12),  Skinlite (+14), Pan (+19), Zincovit (+6), Thyronorm (+30), Pan D (+13), Shelcal (+78), Janumet (+84), Panderm Plus (+64), Levipil (+20)  amongst top 100 brands over November 13

A total of 379 SKUs and 239 brands were launched in November 2014. Top new brands for November are Janumet XR CP, Bio Exidil & Celekast.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit http://www.aiocd.net

Leave A Reply

Your email address will not be published.